334 related articles for article (PubMed ID: 25476252)
1. In Silico Design of Beta-Secretase Inhibitors in Alzheimer's Disease.
Semighini EP
Chem Biol Drug Des; 2015 Sep; 86(3):284-90. PubMed ID: 25476252
[TBL] [Abstract][Full Text] [Related]
2. Inkjet printing-based β-secretase fluorescence resonance energy transfer (FRET) assay for screening of potential β-secretase inhibitors of Alzheimer's disease.
Lee J; Samson AAS; Song JM
Anal Chim Acta; 2018 Aug; 1022():89-95. PubMed ID: 29729742
[TBL] [Abstract][Full Text] [Related]
3. Study on the active mechanism of β-secretase inhibitors by molecular simulations.
Tian YL; Lv M; Li JJ; Xu T; Zhai HL; Zhang XY
Eur J Pharm Sci; 2015 Aug; 76():138-48. PubMed ID: 25965961
[TBL] [Abstract][Full Text] [Related]
4. In vitro antiamyloidogenic properties of 1,4-naphthoquinones.
Bermejo-Bescós P; Martín-Aragón S; Jiménez-Aliaga KL; Ortega A; Molina MT; Buxaderas E; Orellana G; Csákÿ AG
Biochem Biophys Res Commun; 2010 Sep; 400(1):169-74. PubMed ID: 20709023
[TBL] [Abstract][Full Text] [Related]
5. Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features.
Shimmyo Y; Kihara T; Akaike A; Niidome T; Sugimoto H
Biochim Biophys Acta; 2008 May; 1780(5):819-25. PubMed ID: 18295609
[TBL] [Abstract][Full Text] [Related]
6. Novel non-peptide beta-secretase inhibitors derived from structure-based virtual screening and bioassay.
Xu W; Chen G; Liew OW; Zuo Z; Jiang H; Zhu W
Bioorg Med Chem Lett; 2009 Jun; 19(12):3188-92. PubMed ID: 19447035
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
8. Haloperidol inhibits Memapsin 2: innovation by docking simulation and in vitro assay.
Al-Nadaf AH; Taha MO; Aldal'in HK
Pak J Pharm Sci; 2015 Jan; 28(1):139-46. PubMed ID: 25553677
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's disease: identification and development of β-secretase (BACE-1) binding fragments and inhibitors by dynamic ligation screening (DLS).
Fernández-Bachiller MI; Horatscheck A; Lisurek M; Rademann J
ChemMedChem; 2013 Jul; 8(7):1041-56. PubMed ID: 23757181
[TBL] [Abstract][Full Text] [Related]
10. Multiwell fluorometric and colorimetric microassays for the evaluation of beta-secretase (BACE-1) inhibitors.
Mancini F; Naldi M; Cavrini V; Andrisano V
Anal Bioanal Chem; 2007 Jul; 388(5-6):1175-83. PubMed ID: 17541560
[TBL] [Abstract][Full Text] [Related]
11. Design and development of BACE-1 inhibitors.
Cumming JN; Iserloh U; Kennedy ME
Curr Opin Drug Discov Devel; 2004 Jul; 7(4):536-56. PubMed ID: 15338962
[TBL] [Abstract][Full Text] [Related]
12. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo.
Hussain I; Hawkins J; Harrison D; Hille C; Wayne G; Cutler L; Buck T; Walter D; Demont E; Howes C; Naylor A; Jeffrey P; Gonzalez MI; Dingwall C; Michel A; Redshaw S; Davis JB
J Neurochem; 2007 Feb; 100(3):802-9. PubMed ID: 17156133
[TBL] [Abstract][Full Text] [Related]
13. Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimer's disease.
Huang WH; Sheng R; Hu YZ
Curr Med Chem; 2009; 16(14):1806-20. PubMed ID: 19442147
[TBL] [Abstract][Full Text] [Related]
14. Modeling of substrate specificity of the Alzheimer's disease amyloid precursor protein beta-secretase.
Sauder JM; Arthur JW; Dunbrack RL
J Mol Biol; 2000 Jul; 300(2):241-8. PubMed ID: 10873463
[TBL] [Abstract][Full Text] [Related]
15. Computational methods in the discovery and design of BACE-1 inhibitors.
Kacker P; Bottegoni G; Cavalli A
Curr Med Chem; 2012; 19(36):6095-111. PubMed ID: 23072352
[TBL] [Abstract][Full Text] [Related]
16. Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer`s disease.
Silva-Junior EF; Barcellos Franca PH; Quintans-Junior LJ; Mendonca-Junior FJB; Scotti L; Scotti MT; de Aquino TM; de Araujo-Junior JX
Curr Comput Aided Drug Des; 2017 Nov; 13(4):266-274. PubMed ID: 28382866
[TBL] [Abstract][Full Text] [Related]
17. Spirocyclic sulfamides as β-secretase 1 (BACE-1) inhibitors for the treatment of Alzheimer's disease: utilization of structure based drug design, WaterMap, and CNS penetration studies to identify centrally efficacious inhibitors.
Brodney MA; Barreiro G; Ogilvie K; Hajos-Korcsok E; Murray J; Vajdos F; Ambroise C; Christoffersen C; Fisher K; Lanyon L; Liu J; Nolan CE; Withka JM; Borzilleri KA; Efremov I; Oborski CE; Varghese A; O'Neill BT
J Med Chem; 2012 Nov; 55(21):9224-39. PubMed ID: 22984865
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an Allosteric BACE Inhibitor Peptide to Identify Mimetics that Can Interact with the Loop F Region of the Enzyme and Prevent APP Cleavage.
Campagna J; Vadivel K; Jagodzinska B; Jun M; Bilousova T; Spilman P; John V
J Mol Biol; 2018 May; 430(11):1566-1576. PubMed ID: 29649434
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of hydroxyethylamine (HEA) BACE-1 inhibitors: structure-activity relationship of the aryl region.
Probst GD; Bowers S; Sealy JM; Stupi B; Dressen D; Jagodzinska BM; Aquino J; Gailunas A; Truong AP; Tso L; Xu YZ; Hom RK; John V; Tung JS; Pleiss MA; Tucker JA; Konradi AW; Sham HL; Jagodzinski J; Toth G; Brecht E; Yao N; Pan H; Lin M; Artis DR; Ruslim L; Bova MP; Sinha S; Yednock TA; Gauby S; Zmolek W; Quinn KP; Sauer JM
Bioorg Med Chem Lett; 2010 Oct; 20(20):6034-9. PubMed ID: 20822903
[TBL] [Abstract][Full Text] [Related]
20. Aspartic proteases involved in Alzheimer's disease.
Schmidt B
Chembiochem; 2003 May; 4(5):366-78. PubMed ID: 12740808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
